N6-methyladenosine-modified HOTAIRM1 promotes vasculogenic mimicry formation in glioma

Zhangyi Wu1, Yihai Lin1, Nan Wei2

  • 1Department of Neurosurgery, Zhejiang Provincial Tongde Hospital, Hangzhou, China.

Cancer Science
|September 10, 2022
PubMed

Insights

N6-methyladenosine (m6A) modification of HOTAIRM1 RNA, regulated by METTL3, promotes vasculogenic mimicry (VM) in glioma. This finding offers new insights into glioma progression and potential therapeutic targets for VM.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Vasculogenic mimicry (VM) accelerates tumor angiogenesis, but its regulatory mechanisms remain unclear.
  • N6-methyladenosine (m6A) modification influences mRNA fate and tumorigenesis.
  • HOTAIRM1 is implicated in cancer, but its role in glioma VM is not fully understood.

Purpose of the Study:

  • To investigate the role of m6A-modified HOTAIRM1 in regulating VM in glioma.
  • To elucidate the underlying molecular mechanisms connecting m6A, HOTAIRM1, and VM in glioma.

Main Methods:

  • Quantitative RT-PCR for gene expression analysis.
  • Cell viability, migration, invasion, and tube formation assays to assess tumor progression and VM.
  • Liquid chromatography-tandem mass spectrometry, methylated RNA immunoprecipitation sequencing, RNA stability assays, and RNA pull-down experiments to define m6A modification mechanisms.
  • Glioma xenograft mouse model for in vivo VM evaluation.

Main Results:

  • HOTAIRM1, METTL3, and IGFBP2 were upregulated in glioma tissues and cell lines.
  • HOTAIRM1 knockdown reduced glioma cell viability, migration, invasion, and VM formation.
  • METTL3-dependent m6A modification enhanced HOTAIRM1 mRNA stability, suppressing VM upon METTL3 knockdown.
  • HOTAIRM1 interacted with IGFBP2, and HOTAIRM1 deficiency inhibited glioma progression and VM in vivo.

Conclusions:

  • METTL3-dependent m6A modification of HOTAIRM1 promotes VM formation in glioma.
  • HOTAIRM1 acts as an oncogene in glioma progression by facilitating VM.
  • Targeting the METTL3-HOTAIRM1 axis may offer a therapeutic strategy for inhibiting glioma VM.